Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries.
Researchers report how body fat affects imune cells
Latest NewsUS scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
European Lead Factory gets €36.5m support from IMI
Latest NewsThe European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative.
AstraZeneca set to licence 5 programmes from Transgène SA
Latest NewsAlentis Therapeutics debuts with CHF12.5m
Latest NewsLiver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures.
Immunic appoints Tamara A. Seymour as Interim CFO
AppointmentsImmunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries.
EMA recommends nine drugs for market approval
Latest NewsIn its first meeting in Amsterdam, the CHMP of the European Medicines Agency recommended six new drugs, two orphan meds, and one biosimilar for EU market authorisation.
Jo Easton Appointed Non-Executive Director
AppointmentsMedica Group Plc (LSE:MGP) announces that Jo Easton has been appointed to the Group’s Board of Directors as a non-executive director. On joining the Board, Jo will be appointed to the audit, nomination and remuneration committees.
A Holy Grail in the quest to end cancer
BackgroundTargeted therapies and chemotherapeutics have helped cut cancer deaths dramatically in the last few decades. In the US, the overall mortality rate of 251/100,000 patients in 1991 had fallen by 2016 to 156/100,000 patients. Engineered (multispecific) antibodies, cell therapies and combination therapies are expected to continue to increase success rates with primary tumors. And research groups are turning their big guns on what is now the biggest killer – metastasis.
A novel strategy against rheumatoid arthritis
Latest NewsResearchers at AstraZeneca, Viela Bio, Gilead Sciences, Antidote Therapeutics Inc., and at SoseiHeptares report on a new small molecule compound to treat RA.
US patent office grants Charpentier CRISPR patent
Latest NewsThe US Patent Office has granted the Charpentier/Doudna key CRISPR patent, which was previously involved in an interference proceeding.